TALPHERA INC (TLPH) Stock Price, Forecast & Analysis
NASDAQ:TLPH • US00444T2096
TLPH Key Statistics, Chart & Performance
The current stock price of TLPH is 0.7766 USD. In the past month the price decreased by -23.11%. In the past year, price increased by 29.33%.
TLPH Technical Analysis
TLPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TLPH. While TLPH seems to be doing ok healthwise, there are quite some concerns on its profitability.
TLPH Financial Highlights
Over the last trailing twelve months TLPH reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS increased by 44.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.3% | ||
| ROE | -64.6% | ||
| Debt/Equity | 0 |
TLPH Forecast & Estimates
8 analysts have analysed TLPH and the average price target is 3.32 USD. This implies a price increase of 326.86% is expected in the next year compared to the current price of 0.7766.
TLPH Ownership
TLPH Latest News, Press Relases and Analysis
TLPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.08 | 954.38B | ||
| JNJ | JOHNSON & JOHNSON | 20.81 | 584.231B | ||
| MRK | MERCK & CO. INC. | 22.6 | 303.452B | ||
| PFE | PFIZER INC | 8.87 | 151.524B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.97 | 123.489B | ||
| ZTS | ZOETIS INC | 18.75 | 56.752B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.045B | ||
| VTRS | VIATRIS INC | 6.29 | 18.336B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.89 | 12.412B | ||
| AXSM | AXSOME THERAPEUTICS INC | 224.33 | 9.261B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TLPH
Company Profile
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Company Info
TALPHERA INC
1850 Gateway Drive, Suite 175
San Mateo CALIFORNIA US
Employees: 13
Phone: 16502163500
TALPHERA INC / TLPH FAQ
What does TLPH do?
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
What is the stock price of TALPHERA INC today?
The current stock price of TLPH is 0.7766 USD. The price decreased by -3.87% in the last trading session.
Does TALPHERA INC pay dividends?
TLPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of TLPH stock?
TLPH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for TLPH stock?
8 analysts have analysed TLPH and the average price target is 3.32 USD. This implies a price increase of 326.86% is expected in the next year compared to the current price of 0.7766.
Can you provide the sector and industry classification for TALPHERA INC?
TALPHERA INC (TLPH) operates in the Health Care sector and the Pharmaceuticals industry.
What is the outstanding short interest for TALPHERA INC?
The outstanding short interest for TALPHERA INC (TLPH) is 3.71% of its float.